Open AccessPilot study of dietary phosphorus restriction and phosphorus binders to target fibroblast growth factor 23 in patients with chronic kidney disease
Author(s) -
Tamara Isakova,
Orlando M. Gutiérrez,
Kelsey Smith,
M. Epstein,
Louise Keating,
Harald Jüppner,
Myles Wolf
Publication year - 2010
Publication title -
nephrology dialysis transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.654
H-Index - 168
eISSN - 1460-2385
pISSN - 0931-0509
DOI - 10.1093/ndt/gfq419
Subject(s) - medicine , kidney disease , excretion , sevelamer , endocrinology , phosphate binder , lanthanum carbonate , fibroblast growth factor 23 , phosphate , hyperphosphatemia , phosphorus , urinary system , parathyroid hormone , placebo , calcium , chemistry , biochemistry , organic chemistry , pathology , alternative medicine
High levels of fibroblast growth factor 23 (FGF23) are associated with mortality and progression of chronic kidney disease (CKD). Reducing dietary phosphorus intake lowers FGF23 secretion in healthly individuals, but there is little data on its effects in patients with pre-dialysis CKD.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom